KEMPHARM, INC Uncategorized Contracts & Agreements

13 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
KEMPHARM, INC
Pharmaceuticals
2024
Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra Therapeutics, Inc., Computershare, Inc., and Computershare Trust Company, N.A
KEMPHARM, INC
Pharmaceuticals
DE
2023
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
KEMPHARM, INC
Pharmaceuticals
2023
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
KEMPHARM, INC
Pharmaceuticals
2022
Form of Inducement Letter
KEMPHARM, INC
Pharmaceuticals
2021
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
KEMPHARM, INC
Pharmaceuticals
2021
Payoff letter, dated as of February 8, 2021, by and among the Company and the lenders named therein
KEMPHARM, INC
Pharmaceuticals
2021
Form of Inducement Letter
KEMPHARM, INC
Pharmaceuticals
2021
Amended and Restated Bylaws of KemPharm, Inc., effective as of July 15, 2020
KEMPHARM, INC
Pharmaceuticals
DE
2020
Agreement to Terminate CLA, by and between MonoSol Rx, LLC and the Registrant, dated as of March 20, 2012
KEMPHARM, INC
Pharmaceuticals
2019
THIRD AMENDMENT
KEMPHARM, INC
Pharmaceuticals
2017
SECOND AMENDMENT
KEMPHARM, INC
Pharmaceuticals
2017
FIRST AMENDMENT
KEMPHARM, INC
Pharmaceuticals
2017